Skip to main content
. 2020 Jan 28;11:40. doi: 10.3389/fimmu.2020.00040

Figure 4.

Figure 4

Enhanced degranulation of NKG2D+ and DNAM-1+ GM NK-92 cells against selected sarcoma explants and Saos-2 and U-2 OS cell lines is receptor mediated. CD155, DNAM-1, or NKG2D blocking was done 15 min prior to degranulation set up. The assay was set as previously described, at E:T ratio 1:1. (A) Anti-CD155 on tumors and anti-DNAM-1 blocking of WT or DNAM-1+ GM NK-92 cells against primary sarcoma explants and (B) anti-DNAM-1 blocking of WT or DNAM-1+ GM NK-92 cells against Saos-2 and U-2 OS cell lines. (C) Anti-NKG2D blocking of NKG2D+ GM NK-92 cells against primary sarcoma explants and (D) anti-NKG2D blocking of WT or NKG2D+ GM NK-92 cells against Saos-2 and U-2 OS cell lines (results from two independent experiments, means plotted with error bars indicating SD). (E) Comparison of degranulation by DNAM-1 or NKG2D GM NK-92 cells with NK-92 cells co-expressing both receptors against Saos-2 and U-2 OS cells (**** indicates p < 0.0001 with 2-way ANOVA analysis).